Shares of Plandai Biotechnology (PLPL) traded light on Tuesday even after the penny stock became a recommended “BUY” in the recent KonLin Letter. PLPL stock traded triple the 20-day average volume, 51,504, but failed to capture the short-term message of Konrad Kuhn who anticipates Plandai’s income for 2012-2013 to reach $27 million, tripling to $90 million within the next ...
The obviously overvalued penny stock of Organovo Holdings Inc. (ONVO) had their 2nd largest volume trading session Thursday for all the wrong reasons. ONVO stock price rose to as high as $4.50 after falling from their prior Seeking Alpha PR pump high of $10.90 after some of the truths already ...
When pharmaceutical giant Pfizer Inc. (NYSE: PZE) has you on their radar, chances are investors are due for a big pay day. With the Tuesday’s surge in the penny stock of Lpath Inc. (OTC: LPTN), it’s time to get them on your radar and get them there fast. LPTN stock price shot up to as high as 0.84 Tuesday before ...
Trading at under a dime, Advaxis Inc., (OTC: ADXS) stock should be on the list of penny stocks to watch, as we mentioned on Monday. ADXS, a leader in developing the next generation of immunotherapies for cancer and infectious diseases and winner of the 2012 Novartis Best Therapeutic ...
Eddie Van Halen’s ex-wife may be the star of the show, but Cleveland BioLabs Inc. (Nasdaq: CBLI) stock is proving that it really is hot. CBLI stock price has been as high as $2.40 today after the Company announced strong survival results for its randomized, blinded, placebo-controlled efficacy study of CBLB502. CBLI is currently trading up 59.84% at $2.04 ...
Shares in the penny stock of CytRx Corp. (Nasdaq: CYTR) may be on a turn around after closing at $0.323 in the last trading session. In the screen of upgrades and downgrades stocks, CYTR is now covered by Wall Street analysts Roth Capital who set a “buy” rating on the penny stock. CytRx, a biopharmaceutical research and development company specializing in oncology, has gained 15.36% ...
Shares in the penny stock of Palatin Technologies Inc. (NYSE Amex: PTN) is now covered by analysts at Roth Capital with a “buy” rating. Palatin, a biopharmaceutical company dedicated to developing targeted, receptor-specific peptide therapeutics, has seen a significant drop in revenues compared to 2010 but could be looking at a rebound in the short-term.
Six weeks ago, Palatin announced that over 400 premenopausal women, diagnosed with female ...
Continue Reading →
If your trading or investing in penny stocks which are not OTC stocks, then these three pharmaceutical companies have Nasdaq listed shares that you should add to your list of penny stocks to watch immediately: Alexza Pharmaceuticals (ALXA), Zalicus Inc. (ZLCS) and Sunesis Pharmaceuticals (SNSS).
Shares in Alexza Pharmaceuticals (Nasdaq: ALXA) are down -23.98% YTD, more than -95% since ...
Continue Reading →
Shares in Generex Biotechnology (OTC: GNBT) have not been able to rally since their January run when the penny stock hit $0.277. We profiled GNBT as one of our penny stock picks profiled in our newsletter when shares were just $0.1575 securing a 75% gain bottom-to-top. GNBT closed with a slight gain of 0.39% at $0.13 in the ...
February was a tough month for biotech stocks researching stem cells for the treatment and cure of diseases. TickerSpy’s Stem Cell Stocks Index (RXSTM) has slipped nearly 13% since early February being outperformed by the S&P 500 by close to 17% during that time.
Four particular stem cell stocks, all cheap stocks under 5 including 2 penny stocks, should ...
Continue Reading →